8月25日，中国疾病预防控制中心发布《中国流感疫苗预防接种技术指南（2022-2023）》。《指南》指出，目前全球仍然处于新冠大流行，我国北方城市也已经进入秋季，国家流感中心8月中旬发布的流感检测周报显示，北方省份流感活动有所升高。秋冬季和冬春季，很可能出现新冠和流感“双疫”蔓延。

因此，开展甲型流感病毒、乙型流感病毒联合检测，用于临床对疑似患者的辅助诊断，早诊断、早隔离、早治疗，是提高流感治愈率、降低病死率的关键。

WHO建议各国为流感和SARS-CoV-2的共循环做好准备工作。WHO鼓励各国加强综合监测，同时监测流感和SARS-CoV-2，并加强流感疫苗接种的组织调度，以便于在进入流感季节时可以节省检测时间和检测资源。

目前，IVDEAR团队已与多家欧洲临床试验机构达成合作，可承接新冠+流感A/B检测试剂的临床试验，由于拥有多家临床试验机构渠道资源，IVDEAR团队克服了流感A/B样本稀缺的棘手难题，能为IVD企业提供全流程的临床试验研究解决方案服务。

On August 25, the Chinese Center for Disease Control and Prevention issued the Technical Guidelines for Influenza Vaccination in China (2022-2023). The Guide points out that at present, the world is still in a new pandemic, and cities in northern China have entered the autumn. The weekly influenza detection report released by the National Influenza Center in mid August shows that influenza activities in northern provinces have increased. In autumn, winter and winter, it is very likely that a new crown will appear and the "double epidemic" of influenza will spread.

Therefore, the joint detection of influenza A virus and influenza B virus for clinical auxiliary diagnosis of suspected patients, early diagnosis, early isolation and early treatment is the key to improve the cure rate of influenza and reduce the fatality rate.

WHO recommends that countries prepare for the co circulation of influenza and SARS CoV-2. WHO encourages countries to strengthen comprehensive monitoring, monitor influenza and SARS CoV-2 at the same time, and strengthen the organization and scheduling of influenza vaccination, so as to save testing time and testing resources when entering the influenza season.